{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:41:25Z","timestamp":1789170085143,"version":"build-2803163510"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Metastasis-directed stereotactic body radiotherapy (SBRT) may be a viable strategy to defer systemic therapy in patients with oligometastatic cancer due to comorbidities, patient preferences, or concerns about adverse effects. To date, the evidence supporting this approach has not been comprehensively assessed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate systemic therapy\u2013free survival (STFS) for different types of oligometastatic cancer after SBRT alone and to quantify adverse events, quality of life, and oncological outcomes.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n A systematic search of PubMed and EMBASE was conducted on July 10, 2024, to identify potentially eligible studies published after 2009. Forward and backward citation tracking was performed to identify additional relevant studies.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Studies eligible for inclusion in the systematic review were retrospective or prospective with at least 10 patients who received metastasis-directed SBRT and no up-front systemic therapy for oligometastatic cancer (\u22645 metastases) irrespective of primary tumor histology. Required outcomes being reported were STFS, progression-free survival, or overall survival. The subgroup of studies reporting STFS at 1 or 2 years were included in a meta-analysis of these pooled outcomes.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two reviewers independently extracted data using predefined forms and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model was used for meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome of the meta-analysis was the pooled STFS rate at 1 or 2 years.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 29 unique studies (2074 unique patients) included in the systematic review, 13 (984 patients) contributed data to the meta-analysis. The pooled 1- or 2-year STFS rate was 69.7% (95% CI, 57.4%-80.9%) across cancer types. Renal cell cancer demonstrated the highest STFS rate (87.0%; 95% CI, 76.2%-95.2%), followed by prostate cancer (78.1%; 95% CI, 67.4%-87.3%), with lower rates in other cancer types. Among 20 studies reporting adverse events, rates of adverse effects of grade 3 or higher were absent in 15 of 19 studies (79%) and ranged from 2 of 103 (1.9%) to 3 of 34 patients (8.8%) among those that observed severe adverse events.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and meta-analysis, metastasis-directed SBRT alone was associated with meaningful STFS, particularly in patients with oligometastatic prostate or renal cell cancer, with low risks of treatment-related adverse events. These findings suggest that SBRT alone might be an acceptable option instead of immediate systemic therapy in selected patients with oligometastatic cancer.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.49685","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:30:45Z","timestamp":1767025845000},"page":"e2549685","source":"Crossref","is-referenced-by-count":8,"title":["Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Jonas","family":"Willmann","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"},{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"von Wachter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja","family":"Zehnder","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Christopher","family":"Dee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, GROW-Research Institute for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Radiation Oncology, University of British Columbia, British Columbia, Canada"},{"name":"Department of Surgery, Division of Radiation Oncology, BC Cancer and University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mayinger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narek","family":"Shaverdian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Olson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Radiation Oncology, University of British Columbia, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (Maastro Clinic), Research Institute for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Radiotherapy, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"3","key":"zoi251333r1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.02.019","article-title":"Oligometastasis: past, present, future.","volume":"108","author":"Gutiontov","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi251333r2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi251333r3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline.","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"zoi251333r4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions.","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"zoi251333r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114062","article-title":"European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).","volume":"204","author":"Kroese","year":"2024","journal-title":"Eur J Cancer"},{"issue":"8","key":"zoi251333r6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship.","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"zoi251333r7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer.","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"zoi251333r8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"zoi251333r9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"zoi251333r10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document.","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"issue":"7109","key":"zoi251333r11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"zoi251333r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100673","article-title":"Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer.","volume":"43","author":"Baron","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"zoi251333r13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","article-title":"Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.","volume":"11","author":"Berkovic","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"zoi251333r14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"issue":"12","key":"zoi251333r15","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi251333r16","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","article-title":"Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR-5 trial.","volume":"118","author":"Baker","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"zoi251333r17","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.23.00150","article-title":"Long-term outcomes of TROG 13.01 SAFRON II randomized trial of single- versus multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases.","volume":"41","author":"Siva","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi251333r18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer.","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"zoi251333r19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1080\/0284186X.2021.1955970","article-title":"Progression-free survival in patients with 68Ga-PSMA-PET\u2013directed SBRT for lymph node oligometastases.","volume":"60","author":"Werensteijn-Honingh","year":"2021","journal-title":"Acta Oncol"},{"issue":"4","key":"zoi251333r20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial.","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"zoi251333r21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clgc.2020.08.002","article-title":"Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness.","volume":"19","author":"Mazzola","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"zoi251333r22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ctro.2022.08.008","article-title":"Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease.","volume":"37","author":"Willmann","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"zoi251333r23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"issue":"12","key":"zoi251333r24","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00345-018-2477-2","article-title":"Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.","volume":"37","author":"Moyer","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"zoi251333r25","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1016\/j.clgc.2017.03.009","article-title":"Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET\/CT.","volume":"15","author":"Bouman-Wammes","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"zoi251333r26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13014-016-0586-x","article-title":"[(18)F]Choline PET\/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.","volume":"11","author":"Pasqualetti","year":"2016","journal-title":"Radiat Oncol"},{"issue":"1","key":"zoi251333r27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis.","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"zoi251333r28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi251333r29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4149\/neo_2018_180522N333","article-title":"Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?","volume":"66","author":"Augugliaro","year":"2019","journal-title":"Neoplasma"},{"issue":"11","key":"zoi251333r30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s11547-018-0912-5","article-title":"Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.","volume":"123","author":"Loi","year":"2018","journal-title":"Radiol Med"},{"issue":"5","key":"zoi251333r31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.ijrobp.2024.11.084","article-title":"Survival without quality of life deterioration in the GORTEC 2014-04 \u201cOMET\u201d randomized phase 2 trial in patients with head and neck cancer with oligometastases using stereotactic ablative radiation therapy (SABR) alone or chemotherapy and SABR.","volume":"121","author":"Thariat","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi251333r32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.616494","article-title":"Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients.","volume":"10","author":"Burkon","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"zoi251333r33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/1754-9485.13057","article-title":"Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases.","volume":"64","author":"Shahi","year":"2020","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"9","key":"zoi251333r34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12032-018-1190-8","article-title":"Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment\u2013free survival: a cohort study.","volume":"35","author":"Mazzola","year":"2018","journal-title":"Med Oncol"},{"issue":"3","key":"zoi251333r35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canrad.2022.11.002","article-title":"Stereotactic body radiotherapy for mediastinal lymph node with CyberKnife\u00ae: efficacy and toxicity.","volume":"27","author":"Camps-Malea","year":"2023","journal-title":"Cancer Radiother"},{"issue":"1","key":"zoi251333r36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00345-016-1860-0","article-title":"Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.","volume":"35","author":"Ingrosso","year":"2017","journal-title":"World J Urol"},{"issue":"7","key":"zoi251333r37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/ijc.35052","article-title":"Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.","volume":"155","author":"See","year":"2024","journal-title":"Int J Cancer"},{"issue":"5","key":"zoi251333r38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s00066-023-02180-9","article-title":"Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.","volume":"200","author":"Mohamed","year":"2024","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"zoi251333r39","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaoncol.2024.1796","article-title":"Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogressive tumors.","volume":"10","author":"Donovan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi251333r40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.ijrobp.2020.10.011","article-title":"Safety, efficacy, and patterns of failure after single-fraction stereotactic body radiation therapy (SBRT) for oligometastases.","volume":"109","author":"Sogono","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi251333r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109671","article-title":"Repeat stereotactic body radiotherapy for oligometastatic disease.","volume":"184","author":"Willmann","year":"2023","journal-title":"Radiother Oncol"},{"issue":"5","key":"zoi251333r42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi251333r43","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials.","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi251333r44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis.","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10185","key":"zoi251333r45","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"zoi251333r46","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial.","volume":"8","author":"Olson","year":"2022","journal-title":"JAMA Oncol"},{"key":"zoi251333r47","article-title":"Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: real-world data from the E2-Radiate OligoCare cohort.","volume":"45","author":"Bultijnck","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10212","key":"zoi251333r48","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843222\/willmann_2025_oi_251333_1766075681.14209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:30:46Z","timestamp":1767025846000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843222"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.49685","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}